StageIPO | IPO
Date of IPO6/21/2017
BoneSupport specializes in injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT|G is the first CE-marked injectable gentamicin antibiotic eluting ceramic bone graft substitute. CERAMENT|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries.
Missing: BoneSupport's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BoneSupport's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BoneSupport
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BoneSupport is included in 3 Expert Collections, including Advanced Materials.
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Latest BoneSupport News
Apr 27, 2023
Bonesupport : Financials Message : KPI's 4,6 0,3 272,2 -174,0 190,4 0,00 23 255 7 884 -8 626 -436 -1 798 -10 860 201 281 190 399 -61 025 Q1 2023 -26 106 -562 -88 043 -174 869 The Group's segments are North America (NA) and Europe & Rest of the World (EUROW). Other comprises other items, mainly costs for Group functions. Contribution per segment is calculated as net sales minus costs that are directly attributable operating costs. Such costs are related to cost of sales, selling expenses including commissions and fees and research and development expenses. Assets and liabilities are not reported by segment, these are managed and monitored on Group level by management and the Board of directors. Attachments
BoneSupport Frequently Asked Questions (FAQ)
When was BoneSupport founded?
BoneSupport was founded in 1999.
Where is BoneSupport's headquarters?
BoneSupport's headquarters is located at Scheelevagen 19A, Lund.
What is BoneSupport's latest funding round?
BoneSupport's latest funding round is IPO.
How much did BoneSupport raise?
BoneSupport raised a total of $79.98M.
Who are the investors of BoneSupport?
Investors of BoneSupport include HealthCap Venture Capital, Industrifonden, Lundbeckfond Ventures, AP3, Kreos Capital and 9 more.
Who are BoneSupport's competitors?
Competitors of BoneSupport include RxSight, Cagenix, BAROnova, Elute, SpineForm and 12 more.
Compare BoneSupport to Competitors
SpineForm is developing a less invasive spinal deformity surgical treatment. SpineForm's HemiBridge is a spinal implant designed to help correct and straighten spinal deformities in growing children, without the need for a brace or extensive future spinal fusion surgeries.
Minimus Spine is developing ozone injection technology specifically for spinal applications. The company has improved upon the existing technology through a system that creates ozone, and measures its concentration, within in a sterile, syringe-cartridge. This has advantages in terms of sterility and dose assurance, as well as material compatibility, which are vital to the advancement of this technique.
Kyphon develops and markets medical devices designed to restore spinal function using minimally invasive technologies. It offers balloon kyphoplasty, a minimally invasive procedure to treat spinal fractures caused by osteoporosis or cancer. The company was founded in 1994 and is based in Sunnyvale, California.
Biopharmaceutical products for the of spinal cord injuries and other central nervous system disorders.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
TransCorp develops and commercializes minimally invasive surgical instruments and implants for neurosurgical and orthopedic applications.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.